Facebook Twitter LinkedIn
Pharmaceutical Innovation
December 10, 2025

Dimerix Nears a Potential First-in-Class Approval in a High-Value Kidney Disease Market

Accelerated approval pathway for DMX-200 could reshape treatment for FSGS patients Dimerix Ltd (ASX: DXB) is entering what could be the most pivotal phase in its decade-long development journey for DMX-200 (Qytovra®), a drug targeting the rare and devastating kidney disease Focal Segmental Glomerulosclerosis (FSGS). With no approved treatments globally and only five years on […]
Read More
Industrial Scale Production
December 10, 2025

Zeotech Moves Closer to Commercialising Low-Carbon Concrete at Industrial Scale

AusPozzâ„¢ advances toward a DFS and first cash flows as industry partnerships accelerate Zeotech Ltd (ASX: ZEO) has delivered a defining year of progress as it advances its AusPozzâ„¢ Project — a high-reactivity metakaolin product designed to replace up to 50% of cement in concrete. AusPozzâ„¢ offers a rare combination of improved strength, enhanced durability, […]
Read More
Edge-AI and Robotics
December 10, 2025

DorsaVi Enters the Neuromorphic Computing Space With High-Value IP Acquisition

New processing-in-memory technology pushes the company toward next-generation robotics and edge-AI applications DorsaVi Ltd (ASX: DVL) has taken a significant strategic step with the acquisition of neuromorphic processing-in-memory (PIM) intellectual property from Technion in Israel — technology led by Professor Shahar Kvatinsky, one of the semiconductor industry’s most prominent neuromorphic hardware researchers. This move positions […]
Read More
December 10, 2025

Prescient Advances a Potentially Pivotal Cancer Trial with Multiple Near-Term Catalysts

Phase 2 progress strengthens the commercial outlook for PTX-100 in hard-to-treat T-Cell Lymphoma Prescient Therapeutics (ASX: PTX) is progressing through a critical development phase with its lead drug candidate, PTX-100, currently in a global Phase 2 clinical trial for relapsed/refractory Cutaneous T-Cell Lymphoma (r/r CTCL). The drug is believed to be the only GGT-1 inhibitor […]
Read More
Adisyn Ltd
November 27, 2025

Adisyn Takes a Key Step Forward in Graphene Chip Technology

Validation of a critical manufacturing stage brings Adisyn closer to commercialising next-generation semiconductor interconnects Adisyn Ltd (ASX: AI1) has reached an important technical milestone in the development of its graphene-based semiconductor technology, ticking off a crucial early step on the path toward commercial deployment. Through its IP subsidiary, 2D Generation (2DG), the company has successfully […]
Read More